Business Wire

Aeonsemi Unveils ChronoPHY™ Series of Multi-Rate 10G Ethernet PHYs, Industry’s Highest Performing Ethernet Transceivers for Broadband Access, Intelligence Computing, and Industrial applications.


Aeonsemi (, an innovator of mixed-signal and DSP communications ICs, announced today the launch of the ChronoPHY™ series of high-performance, low-latency physical layer ethernet transceivers. The ground up architecture is designed to meet the bandwidth, synchronization, latency, and robustness requirements of modern networks that enable emerging real-time collaboration, immersive augmented and virtual reality applications. Leveraging an advanced DSP and timing architecture, these transceivers can achieve sub-nanosecond network synchronization accuracy and determinism, surpassing competing solutions by over 10 times with great power efficiency. The PHYs also integrate a SyncE jitter filtering PLL function, ensuring reliable link performance and simplified signal integrity design without the need for additional external components.

“High resolution video transmission, streaming, gaming, and AR/VR applications are fueling the demand for faster, lower-latency, and more deterministic networks,” said Yunteng Huang, CEO of Aeonsemi. “With the roll out of WiFi-6, WiFi-7 and 10G broadband access into homes and businesses, the residential and enterprise LAN infrastructure is rapidly upgrading to support multi-gigabit capabilities. The ChronoPHY™ family is specifically positioned to facilitate the adoption of these faster networks, making the convenience and efficiency improvement accessible to everyone across the economic spectrum.”

The ChronoPHY™ series is designed on TSMC’s advanced process node and employs an efficient frequency domain digital signal processing system architecture. This enables the PHYs to achieve the industry-leading cable reach and interference immunity, ensuring robust and reliable performance.

Compliant with IEEE802.3 & IEEE1588 standards, the ChronoPHY™ series is specified over the industrial temperature range of –40C to +85C with single port options housed in 7mm x 7mm and 11mm x 11mm BGA packages. Samples and evaluation kits are available now with production to start in September.

ChronoPHY™ Series Highlights:

  • 10GBase-T, 5GBase-T, 2.5GBase-T, 1000Base-T, and 100Base-TX
  • IEEE802.3an/802.3bz/802.3ab/802.3u compliant
  • IEEE1588 network synchronization with integrated timing functions
    • 1ns PTP time stamping resolution
    • Flexible reference input clock of 50MHz or 156.25MHz
    • Any rate fractional frequency SyncE output clock: 25MHz to 250MHz
    • Ultra-low close-in phase noise SyncE PLL

About Aeonsemi

Founded by technologists in mixed-signal, DSP, and systems design, Aeonsemi brings innovative high-speed interface and timing solutions to customers and solves complex technical challenges in networking, computing, wireless infrastructure, industrial, and automotive applications.

To view this piece of content from, please give your consent at the top of this page.

Contact information

T: (650) 308-9669

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 20:43:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an

Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 17:30:00 EEST | Press release

Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc

GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine29.9.2023 16:15:00 EEST | Press release

GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases such as pancreatic cancer and other solid tumors with poor life expectancy. The combined company will have a unique advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance the fields of diagnosis and treatment with

Offshore Windfarm Hollandse Kust Zuid Inaugurated29.9.2023 14:53:00 EEST | Press release

Today, Dutch King Willem-Alexander jointly with the board members of Vattenfall, BASF, and Allianz officially inaugurated the offshore wind farm Hollandse Kust Zuid 1-4. The wind farm is in the North Sea, 18-36 kilometers off the Dutch coast between the towns of Scheveningen and Zandvoort. The 139 turbines have a total capacity of 1.5 GW, making it one of the largest offshore wind farms in the world. The annual electricity production is expected to equal the consumption of 1.5 million households. Hollandse Kust Zuid is owned by Vattenfall, BASF, and Allianz. The wind farm is expected to be fully operational in 2024 and will be serviced out of the port of IJmuiden. This press release features multimedia. View the full release here: Inauguration Hollandse Kust Zuid wind farm. From left to right: Helene Biström (Senior Vice President, Head of Business Area Wind Vattenfall), Martijn Hagens (CEO Vattenfall Netherlands), His Majesty K

The Estée Lauder Companies Launches 2023 Breast Cancer Campaign: Beautifully United to Help End Breast Cancer29.9.2023 14:00:00 EEST | Press release

For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all. This October, The Estée Lauder Companies (ELC) honors Breast Cancer Awareness Month by launching The Campaign in support of the global breast cancer community. As ELC’s largest corporate social impact program, The Campaign continues to inspire purpose-driven action and is a cornerstone of the company’s social investments in women’s advancement, health and education. Through The Campaign, ELC has also been a longstanding supporter of women in science, research and medicine – funding numerous grants and programs around the world and accelerating opportunities for women in STEM. The Campaign was founded by Evelyn H. Lauder in 1992 with the launch of the iconic Pink Ribbon. At a time when breast cancer wasn’t spoken about openly, Evelyn and ELC saw an opportunity to bring awareness to the disease and address stigmas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom